Business Segments · Adjusted EBITDA
Specialties — Adjusted EBITDA
Albemarle Specialties — Adjusted EBITDA increased by 11.1% to $76.13M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 29.8%, from $58.67M to $76.13M. Over 4 years (FY 2021 to FY 2025), Specialties — Adjusted EBITDA shows a downward trend with a -12.4% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementSegment
CategoryProfitability
SignalHigher is better
VolatilityModerate
First reportedQ1 2021
Last reportedQ1 2026
How to read this metric
Higher EBITDA indicates improved operational performance and stronger cash flow generation potential.
Detailed definition
Measures the operational profitability of the Specialties segment by adding back depreciation, amortization, and other n...
Peer comparison
The standard benchmark for comparing operational profitability across all public companies.
Metric ID:
alb_segment_specialties_adjusted_ebitdaHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $117.21M | $117.21M | $117.21M | $152.60M | $147.37M | $133.56M | $93.78M | $162.16M | $60.20M | $46.31M | $29.84M | $45.18M | $54.18M | $56.27M | $72.88M | $58.67M | $72.98M | $75.54M | $68.55M | $76.13M |
| QoQ Change | — | +0.0% | +0.0% | +30.2% | -3.4% | -9.4% | -29.8% | +72.9% | -62.9% | -23.1% | -35.6% | +51.4% | +19.9% | +3.9% | +29.5% | -19.5% | +24.4% | +3.5% | -9.3% | +11.1% |
| YoY Change | — | — | — | — | +25.7% | +13.9% | -20.0% | +6.3% | -59.2% | -65.3% | -68.2% | -72.1% | -10.0% | +21.5% | +144.2% | +29.8% | +34.7% | +34.2% | -5.9% | +29.8% |
Range$29.84M – $162.16M
CAGR-8.7%
Avg YoY Growth+2.5%
Median YoY Growth+10.1%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Albemarle's specialties — adjusted ebitda?
- Albemarle (ALB) reported specialties — adjusted ebitda of $76.13M in Q1 2026.
- How has Albemarle's specialties — adjusted ebitda changed year-over-year?
- Albemarle's specialties — adjusted ebitda increased by 29.8% year-over-year, from $58.67M to $76.13M.
- What is the long-term trend for Albemarle's specialties — adjusted ebitda?
- Over 4 years (2021 to 2025), Albemarle's specialties — adjusted ebitda has grown at a -12.4% compound annual growth rate (CAGR), from $468.84M to $275.74M.
- What does specialties — adjusted ebitda mean?
- The core cash-based operating profit of the Specialties segment.